Pricing Log in Create free account
Saturday 17 October 2026 Export VTRS’s income statement to Excel — free account

Viatris Inc.

VTRS Healthcare Drug Manufacturers Specialty & Generic

Viatris Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, down 2.98% from fiscal 2024. In the quarter to June 2026, revenue grew 4.88%, EPS fell 2,464.1%, free cash flow grew 101.1% and total debt fell 18.1%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for five consecutive years.

18.66 0.44 +2.41%
Market cap
$20.9B
P/E
0.0×
Fwd P/E
61.1×
Dividend yield
2.57%
F-score
4/9
Altman Z
0.61
Beneish M
−3.29
Dividend safety
37/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Viatris Inc. (VTRS) Business Profile

Updated before January 2025

Company Overview

Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that was formed in November 2020 through the merger of Mylan N.V. and Upjohn, a division of Pfizer. Headquartered in Canonsburg, Pennsylvania, Viatris operates in over 165 countries and territories, providing access to a broad range of medicines, including generics, branded medications, biosimilars, and over-the-counter products. The company’s mission is to empower people worldwide to live healthier lives at every stage of life by providing sustainable access to high-quality medicines.

Viatris is led by a seasoned leadership team with extensive experience in the pharmaceutical and healthcare industries. As of 2023, the company’s CEO is Scott A. Smith, who brings a wealth of expertise in global operations and strategic growth. Other key members of the leadership team include Sanjeev Narula as Chief Financial Officer and Michael Goettler, who played a pivotal role in the company’s formation and initial strategic direction.

Core Business Segments

Viatris operates across three primary business segments, offering a diverse portfolio of products and services:

1. Generics and Biosimilars

Viatris is a leading provider of generic medicines and biosimilars, which are cost-effective alternatives to branded drugs. The company’s portfolio includes treatments for a wide range of therapeutic areas, such as cardiovascular diseases, diabetes, oncology, and infectious diseases. Notable products in this segment include:

  • Insulin Glargine: A biosimilar for diabetes management.
  • Fulphila: A biosimilar to Neulasta, used to reduce the risk of infection during chemotherapy.
  • Generic EpiPen: A cost-effective alternative to the branded epinephrine auto-injector for severe allergic reactions.

2. Branded Medicines

Viatris offers a range of branded medications that address chronic and acute conditions. These products are often well-established in the market and include treatments for central nervous system disorders, respiratory conditions, and dermatological issues. Key branded products include:

  • Lyrica: Used for neuropathic pain and fibromyalgia.
  • Lipitor: A cholesterol-lowering medication.
  • Celebrex: A nonsteroidal anti-inflammatory drug (NSAID) for pain relief.

3. Over-the-Counter (OTC) Products

The company also provides a variety of OTC products that cater to consumer health needs. These include vitamins, supplements, and treatments for common ailments such as colds, allergies, and digestive issues. Popular OTC products include:

  • Theraflu: A remedy for cold and flu symptoms.
  • Emergen-C: A vitamin C supplement for immune support.
  • Dramamine: A treatment for motion sickness.

Business Model

Viatris’s business model is centered on integrating its diverse portfolio of products and services to create a sustainable and scalable healthcare platform. The company generates revenue through the sale of prescription medicines, biosimilars, and OTC products. Its global reach and extensive manufacturing capabilities enable it to deliver high-quality medicines at competitive prices.

Viatris also invests heavily in research and development (R&D) to expand its product portfolio and bring innovative treatments to market. The company collaborates with healthcare providers, governments, and other stakeholders to improve access to medicines, particularly in underserved regions. Additionally, Viatris leverages its robust supply chain and distribution network to ensure timely delivery of products worldwide.

Strategic Direction

Viatris has outlined several strategic priorities to drive future growth and sustainability:

  • Portfolio Expansion: The company aims to develop and launch new biosimilars and generic medicines to address unmet medical needs.
  • Digital Transformation: Viatris is investing in digital technologies to enhance its operations, improve patient engagement, and streamline supply chain management.
  • Sustainability Goals: The company is committed to reducing its environmental footprint by adopting sustainable manufacturing practices and minimizing waste.
  • Geographic Expansion: Viatris plans to strengthen its presence in emerging markets, where demand for affordable healthcare solutions is growing rapidly.
  • Patient-Centric Initiatives: The company is focused on improving patient outcomes through education, support programs, and partnerships with healthcare providers.

Competitive Landscape

Viatris operates in a highly competitive pharmaceutical industry, facing competition from both large multinational corporations and smaller regional players. Key competitors include:

  • Teva Pharmaceuticals: A leading provider of generic medicines and biosimilars.
  • Sandoz (a division of Novartis): Specializes in generics and biosimilars.
  • Amgen: Focuses on innovative biologics and biosimilars.
  • Pfizer: Competes in branded medicines and biosimilars.
  • Sun Pharma: A major player in generics and specialty pharmaceuticals.

Despite the intense competition, Viatris differentiates itself through its extensive product portfolio, global reach, and commitment to affordability and accessibility.

Risk Factors

Viatris faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The pharmaceutical industry is heavily regulated, and changes in laws or policies could affect the company’s ability to market and sell its products.
  • Market Dependence: A significant portion of Viatris’s revenue comes from a few key products, making it vulnerable to market fluctuations and competition.
  • Supply Chain Disruptions: The company relies on a complex global supply chain, which could be affected by geopolitical tensions, natural disasters, or pandemics.
  • Pricing Pressure: Increasing demand for affordable medicines and government policies aimed at reducing healthcare costs could impact profit margins.
  • Litigation Risks: Like many pharmaceutical companies, Viatris is subject to legal challenges, including patent disputes and product liability claims.

Recent Developments

In recent years, Viatris has made significant strides in expanding its product portfolio and enhancing its operational efficiency. Key developments include:

  • Launch of New Biosimilars: The company introduced several biosimilars, including a biosimilar to Humira, to address growing demand for cost-effective biologics.
  • Strategic Partnerships: Viatris entered into collaborations with other pharmaceutical companies to co-develop and commercialize new treatments.
  • Digital Initiatives: The company implemented advanced analytics and automation tools to optimize its supply chain and improve decision-making.
  • Global Expansion: Viatris strengthened its presence in emerging markets, particularly in Asia and Latin America, through targeted investments and partnerships.

Investment Considerations

Investors considering Viatris should weigh the following strengths and risks:

Strengths

  • Diverse product portfolio spanning generics, biosimilars, and branded medicines.
  • Global presence with operations in over 165 countries.
  • Strong commitment to affordability and accessibility.
  • Robust R&D pipeline focused on innovation and unmet medical needs.
  • Experienced leadership team with a proven track record.

Risks

  • Exposure to regulatory and pricing pressures.
  • Dependence on a few key products for a significant portion of revenue.
  • Potential supply chain disruptions and geopolitical risks.
  • Intense competition from established players and new entrants.

Conclusion

Viatris Inc. is a prominent player in the global pharmaceutical industry, offering a wide range of high-quality medicines and healthcare solutions. With its diverse product portfolio, extensive global reach, and commitment to innovation, the company is well-positioned to address the evolving needs of patients and healthcare systems worldwide. While challenges such as regulatory pressures and competition persist, Viatris’s strategic initiatives and focus on sustainability provide a solid foundation for future growth. As the company continues to expand its portfolio and geographic footprint, it remains a compelling choice for investors seeking exposure to the healthcare sector.